Article
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
AIDS (London, England) - 15 May 2017
Bolton Moore Carolyn, Capparelli Edmund V, Samson Pearl, Bwakura-Dangarembizi Mutsa, Jean-Philippe Patrick, Worrell Carol, Heckman Barbara, Purdue Lynette, Spector Stephen A, Benns Alex, Borkowsky William, Loftis Amy, Hawkins Elizabeth, Wallis Carole, Chadwick Ellen G
Abstract excerpt
OBJECTIVES: To determine safety-specific, efficacy-specific and genotypic-specific dose requirements of efavirenz (EFV) in children aged 3 to less than 36 months with HIV infection. DESIGN: IMPAACT P1070 was a 24-week prospective cohort trial of EFV (as open capsules) and two nucleoside reverse transcriptase inhibitors in children with HIV infection 3 to less than 36 months without tuberculosis (Cohort 1)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.